Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon

Brazilian Journal of Infectious Diseases

Volumn 14, Issue 4, 2010, Pages 330-334

  da Ferreira, Sandro Costa ^a   de Vasconcelos Carneiro, Marcos ^a   Souza, Fernanda Fernandes ^a   Teixeira, Andreza Corrêa ^a   Villanova, Marcia Guimarães ^a   de Figueiredo, José Fernando Castro ^b   Passos, Afonso Dinis Costa ^c   Ramalho, Leandra Naira Zambelli ^a   Zucoloto, Sergio ^a   de Martinelli, Ana Lourdes Candolo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Division of Infectious Diseases   (Brazil)

^c Department of Social Medicine ^*  (Brazil)

Author keywords

Follow up; HCV; Hepatitis C; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA2 INTERFERON; INTERFERON; INTERLEUKIN 6; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROGNOSIS; QUALITATIVE ANALYSIS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 78149476528     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702010000400003     Document Type: Article

References (30)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13:2436-41.
2. Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44:20-9.
3. Hoofnagle JH, Lau D. Chronic viral hepatitis-benefits of current therapies. N Engl J Med 1996; 334:1470-1.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alpha- 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
5. Hadziyannis SJ, Sette Jr H, Morgan TR et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
6. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-71.
7. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alpha- 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-92.
8. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352:1426-32.
9. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for the initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
10. Desmond CP, Roberts SK, Dudley F et al. Sustained virological response rates and durability of the response to interferonbased therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006; 13:311-5.
11. Yoshida H, Tateishi R, Arakawa Y et al. Benefit of interferon therapy in hepatocelular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53:425-30.
12. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132:517-24.
13. Marcellin P, Boyer N, Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127:875-81.
14. Formann E, Steindl-Munda P, Hofer H et al. Long-term follow- up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006; 23:507-11.
15. Khokhar N. Late relapse in chronic hepatitis C after sustained viral response to interferon and ribavirin. J Gastroenterol Hepatol 2004; 19:471-2.
16. Veldt BJ, Saracco G, Boyer N et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53:1504-8.
17. Yamaura T, Matsumoto A, Rokuhara A et al. Development of small hepatocellular carcinoma in a patient with chronic hepatitis C after 77 months of a sustained and complete response to interferon therapy. J Gastroenterol Hepatol 2002; 17:1229-35.
18. Chavalitdhamrong D, Tanwandee T. Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. World J Gastroenterol 2006; 12:5532-5.
19. Bruno S, Battezzati PM, Bellati G et al. Long-term beneficial effects in sustained responders to interferon-alpha therapy for chronic hepatitis C. J Hepatol 2001; 34:748-55.
20. Lau DT, Kleiner DE, Ghany MG et al. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28:1121-7.
21. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-5.
22. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-20.
23. Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C. J. Viral Hepat 1999; 6:237-42.
24. Reichard O, Glaumann H, Fryden A et al. Two year biochemical, virological and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alpha-2b treatment. Hepatology 1995; 21:918-22.
25. Swain M, Lai MY, Shiffman ML et al. Durability of sustained virological response (SVR) after treatment with peginterferon alpha 2a (40 kD) (PEGASYS) alone or in combination with ribavirin (Copegus): results of an ongoing longterm follow-up study. Hepatology 2 2004; 40(Suppl 1):400A; AASLD 2004. [Abstract].
26. Larghi A, Tagger A, Crosignani A et al. Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy. J Med Virol 1998; 55:7-11.
27. McHutchison JG, Poynard T, Esteban-Mur R et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002; 35:688-93.
28. Tsuda N, Yuki N, Mochizuki K et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004; 74:406-13.
29. Kobayashi S, Takeda T, Enomoto M et al. Development of hepatocelular carcinoma in patients with chronic hepatitis C who has a virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int 2007; 27:186-91.
30. Ikeda M, Fujiyama S, Tanaka M et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005; 40:148-56.